634 completed, 270 terminated, 158 recruiting, 128 unknown. 1411 Phase 2, 451 Phase 1, 21 Phase 3.
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Fianlimab, Cemiplimab - Melanoma (Skin) | Phase 2 | Not yet recruiting | University of California, Irvine | 35 | 2026-12-01 | 2026-09-11 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Not yet recruiting | University of California, San Diego | 34 | 2026-11-01 | 2026-09-03 |
| Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 46 | 2026-11-01 | 2026-09-14 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study. Pembrolizumab neoadjuvant treatment, surgery, Adjuvant treatment - Stage IIB Melanoma, Stage IIC Melanoma | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 19 | 2026-11-01 | 2026-10-20 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors BL-M08D1 - Melanoma, Solid Tumors | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-10-13 | 2026-10-29 |
| MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. Immune Checkpoint Inhibitors - Melanoma, Advanced Melanoma | Phase 2 | Recruiting | Swiss Cancer Institute | 108 | 2026-10-12 | 2026-10-27 |
| Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma Ipilimumab, Nivolumab - Melanoma | Phase 2 | Withdrawn | University of Utah | 2026-10-01 | 2026-10-19 | |
| Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV | Phase 2 | Recruiting | Sun Yat-sen University | 28 | 2026-10-01 | 2026-09-29 |
Showing 20 of 1411. Sign in to see all of them.
Melanoma (1334) · Carcinoma, Non-Small-Cell Lung (147) · Neoplasm Metastasis (136) · Uveal Melanoma (134) · Carcinoma, Renal Cell (108) · Neoplasms (106) · Breast Neoplasms (69) · Skin Neoplasms (68) · Colorectal Neoplasms (63) · Squamous Cell Carcinoma of Head and Neck (62) · Ovarian Neoplasms (61) · Brain Neoplasms (59) · Lung Neoplasms (53) · Sarcoma (47) · Stomach Neoplasms (46)
Neoplasms by Histologic Type (1407) · Neoplasms, Nerve Tissue (1403) · Neuroectodermal Tumors (1403) · Neoplasms, Germ Cell and Embryonal (1402) · Neuroendocrine Tumors (1400) · Neoplasms by Site (1396) · Skin Diseases (1338) · Skin and Connective Tissue Diseases (1338) · Neoplasms (1305) · Skin Neoplasms (1270) · Neoplasms, Glandular and Epithelial (207) · Urogenital Diseases (197) · Female Urogenital Diseases (191) · Female Urogenital Diseases and Pregnancy Complications (191)
pembrolizumab (175) · Nivolumab (170) · Ipilimumab (159) · aldesleukin (98) · Cyclophosphamide (81) · Interleukin-2 (72) · Temozolomide (58) · Dacarbazine (47) · trametinib (44) · dabrafenib (41) · fludarabine phosphate (40) · fludarabine (39) · Bevacizumab (35) · sargramostim (33) · Paclitaxel (31)
National Cancer Institute (NCI) (139) · M.D. Anderson Cancer Center (49) · Bristol-Myers Squibb (28) · Memorial Sloan Kettering Cancer Center (25) · H. Lee Moffitt Cancer Center and Research Institute (19) · Novartis Pharmaceuticals (17) · Hoffmann-La Roche (15) · GlaxoSmithKline (14) · Merck Sharp & Dohme LLC (14) · Dana-Farber Cancer Institute (12) · Peking University Cancer Hospital & Institute (12) · Pfizer (11) · National Institutes of Health Clinical Center (CC) (10) · Alliance for Clinical Trials in Oncology (9) · Craig L Slingluff, Jr (9)
United States (924) · Australia (130) · Germany (124) · France (122) · Spain (112) · United Kingdom (107) · Italy (103) · Canada (83) · China (80) · Belgium (66) · Netherlands (59) · Switzerland (56) · Poland (37) · Israel (34) · South Korea (34)
Steven A. Rosenberg, MD, PhD (21) · Steven A Rosenberg, M.D. (20) · Antoni Ribas, MD (6) · Craig L. Slingluff, MD (6) · F. Stephen Hodi, MD (6) · Jeffrey S. Weber, MD, PhD (6) · Nina Bhardwaj, MD, PhD (6) · Paul Chapman, MD (6)
PMID 36648215, PMID 25667295, PMID 22555974, PMID 23861247, PMID 24983357, PMID 31401903, PMID 32747469, PMID 34754076, PMID 24408395, PMID 25432172, PMID 26446943, PMID 28592387, PMID 31406564, PMID 33990415, PMID 34132224, PMID 34376578, PMID 34464163, PMID 34774225, PMID 34986285, PMID 37328287, PMID 37934000, PMID 39462179, PMID 40341199, PMID 40721981, PMID 41811823, PMID 10741392, PMID 11874634, PMID 12039921, PMID 12826605, PMID 12947072, PMID 14577912, PMID 14581425, PMID 15073859, PMID 15122079, PMID 15534491, PMID 15598954, PMID 16007689, PMID 16034524, PMID 16087944, PMID 16170182, PMID 16237114, PMID 16260693, PMID 16283570, PMID 16314647, PMID 16344433, PMID 16565971, PMID 16706633, PMID 16710345, PMID 16741252, PMID 16947019
2023 (23), 2019 (12), 2018 (10), U10CA032102 (10), 2015 (9), 2016 (9), 2014 (8), 2025 (8), P30CA008748 (8), U10CA180820 (7), 2008 (6), N01CM62206 (6), U10CA021115 (6), 2004 (5), 2009 (5)